الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 137 |  |  |
| | | from | 137 | | |
Abstract
Hepatitis C virus (HCV) is a globally prevalent pathogen and a leading cause of death and morbidity. Hepatitis C virus (HCV) infection is a major public health threat worldwide, with approximately 71 million people living with chronic infection. In Egypt, where an estimated 6.3% of the population may have chronic hepatitis C, over 90% of the infections have been reported to be HCV genotype 4. Direct-acting antiviral (DAA) agents have increased SVR rates to over 90% with dramatically improved side effect profiles. However, there is limited data on the effects of DAA therapy on lipid profiles as well as body mass index. Aim of the work: The current study aims to assess the impact of direct acting antiviral agents on lipid profile, hemoglobin and body mass index in Egyptian chronic hepatitis C patients. Patient and methods: The study included 100 cases (n = 100) diagnosed with chronic hepatitis C infection and commenced on Direct-acting antiviral (DAA) treatment regimen. Results: Cholesterol, LDL and albumin showed a significant increase after treatment. HDL, triglycerides, hemoglobin and BMI showed no significant changes after treatment.